JD Supra3h
GLP-1 Weight-Loss Drugs Off Shortage List; Deadlines to Stop Compounding
Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the ...
Medscape5h
Should ‘Time in Tight Range’ Be the Primary Diabetes Goal?
ATTD conference, experts debated whether patients who use continuous glucose monitoring should aim for normal glycemia.
Carlsbad’s Ionis strikes deal with Japanese pharma worth up to $940M
Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine ...
The Case For Hims & Hers: Diversification And Growth Beyond Semaglutide
Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.